We are live on ! Find out more
ARMO

ARMO BioSciences, Inc. Common Stock
ARMO

Delisted

ARMO was delisted on the 21st of June, 2018.

Back to rankings

65 hedge funds and large institutions have $509M invested in ARMO BioSciences, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 65 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
65
Holders Change
+65
Holders Change %
–
% of All Funds
1.49%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
65
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
O
OrbiMed
New York
+$173M
2
AI
Alphabet Inc
California
+$51.1M
3
ACA
Avoro Capital Advisors
New York
+$50.8M
4
BlackRock
BlackRock
New York
+$34.6M
5
HH
HSG Holding
Hong Kong
+$34M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$154M +$173M +4,118,903 New
AI
2
Alphabet Inc
California
$45.4M +$51.1M +1,214,700 New
ACA
3
Avoro Capital Advisors
New York
$45.2M +$50.8M +1,207,500 New
BlackRock
4
BlackRock
New York
$30.8M +$34.6M +822,167 New
HH
5
HSG Holding
Hong Kong
$30.3M +$34M +809,800 New
Jennison Associates
6
Jennison Associates
New York
$18.4M +$20.7M +493,061 New
RI
7
RTW Investments
New York
$14M +$17.4M +413,892 New
JP Morgan Chase
8
JP Morgan Chase
New York
$12.4M +$14M +332,548 New
CCP
9
Clough Capital Partners
Massachusetts
$12M +$13.8M +328,351 New
EA
10
Emerald Advisers
Pennsylvania
$11.4M +$12.8M +304,330 New
FM
11
Frazier Management
Washington
$11.2M +$12.6M +300,000 New
RG
12
Redmile Group
California
$11.2M +$12.6M +298,800 New
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$10.4M +$11.7M +277,339 New
Wells Fargo
14
Wells Fargo
California
$10.1M +$11.4M +270,387 New
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
$9.73M +$10.9M +260,185 New
BM
16
Bridger Management
New York
$8.68M +$9.76M +232,115 New
DM
17
Deerfield Management
New York
$7.05M +$7.92M +188,525 New
Franklin Resources
18
Franklin Resources
California
$6.55M +$7.36M +175,000 New
Millennium Management
19
Millennium Management
New York
$5.42M +$6.09M +144,821 New
UBS AM
20
UBS AM
Illinois
$4.59M +$5.16M +122,643 New
Vanguard Group
21
Vanguard Group
Pennsylvania
$4M +$4.49M +106,883 New
State of New Jersey Common Pension Fund D
22
State of New Jersey Common Pension Fund D
New Jersey
$3.74M +$4.2M +100,000 New
State Street
23
State Street
Massachusetts
$3.46M +$3.89M +92,440 New
PC
24
PointState Capital
New York
$3.04M +$3.42M +81,400 New
ACP
25
Acuta Capital Partners
California
$2.99M +$3.36M +80,000 New
1
2 3

ARMO Hedge Fund Activity: Q1 2018 in Review

65 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ARMO BioSciences, Inc. Common Stock (ARMO) for Q1 2018, worth a combined $509M.

Buyers outnumbered sellers: 65 funds opened new ARMO positions and 0 closed out — a net gain of 65 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $173M.

  • 65 institutional investors held ARMO BioSciences, Inc. Common Stock (ARMO) as of Q1 2018, up from 0 in Q4 2017.
  • Funds reported $509M of ARMO BioSciences, Inc. Common Stock stock for Q1 2018.
  • 65 funds opened new ARMO BioSciences, Inc. Common Stock positions in Q1 2018 and 0 closed out, a net change of +65 holders.
  • The largest ARMO BioSciences, Inc. Common Stock buyer in Q1 2018 was OrbiMed, an estimated $173M added.

Based on aggregated 13F filings for Q1 2018.